EN PL
GERIATRICS / ORIGINAL PAPER
Osteoporosis and polymorphisms of osteoprotegerin gene in postmenopausal women – a pilot study
 
More details
Hide details
 
Submission date: 2016-01-14
 
 
Final revision date: 2016-02-23
 
 
Acceptance date: 2016-03-01
 
 
Online publication date: 2016-03-24
 
 
Publication date: 2016-02-29
 
 
Reumatologia 2016;54(1):10-13
 
KEYWORDS
TOPICS
ABSTRACT
Objectives: Osteoprotegerin (OPG) has an important role in bone remodeling, and it has been proposed that the OPG gene might be a candidate gene for osteoporosis predisposition. Several studies have already assessed the connection between OPG gene polymorphism and bone mineral density (BMD). In this study we wanted to analyze the association of two polymorphisms in the OPG gene with BMD and bone turnover markers in women with and without osteoporosis.
Material and methods: In 22 postmenopausal women with osteoporosis (aged 65.6 ±12.6) and 59 women without osteoporosis (aged 60.8 ±8.7) we analyzed the association of two polymorphisms in the OPG gene with BMD, measured by dual energy absorptiometry and with bone turnover markers (crosslaps and osteoprotegerin). A163G, G209A, T245G and G1181C polymorphisms were determined.
Results: No significant differences in age, anthropometry, number of fractures, osteocalcin and cross-laps were found between women with and without osteoporosis. Women with osteoporosis were significantly longer in postmenopause. Significantly more women with osteoporosis had AG polymorphism (p = 0.038) compared to women without osteoporosis, while no significant difference was found in prevalence of TT and GG polymorphism between patients with and without osteoporosis. No relationship was found between investigated polymorphism and bone turnover markers. A significant negative correlation between total hip BMD and crosslaps (p = 0.046) as well as between total hip T score and crosslaps (p = 0.044) was found in women without osteoporosis
Conclusions: Postmenopausal women with osteoporosis had AG polymorphism more frequently than women without osteoporosis. Our results indicate that A163G polymorphism could have an impact on higher bone loss in postmenopausal women.
 
REFERENCES (13)
1.
Vega D, M, Sakhaee K. The role of receptor activator of nuclear factor-kappa B (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab 2007; 92: 4514-4521.
 
2.
Pivonka P, Zimak J, Smith DW, et al. Theoretical investigation of the role of the RANK–RANKL–OPG system in bone remodeling. J Theor Biol 2010; 262: 306-316.
 
3.
Langdahl BL, Carstens M, Stenkjaer L, Eriksen EF. Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures. J Bone Miner Res 2002; 17: 1245-1255.
 
4.
Arko B, Prezelj J, Kocijancic A, et al. Association of the osteoprotegerin gene polymorphisms with bone mineral density in postmenopausal women. Maturitas 2005; 51: 270-279.
 
5.
Ohmori H, Makita Y, Funamizu M, et al. Linkage and association analyses of the osteoprotegerin gene locus with human osteoporosis. J Hum Genet 2002; 47: 400-406.
 
6.
Wynne F, Drummond F, O’sullivan K, et al. Investigation of the genetic influence of the OPG, VDR (Fok1), and COLIA1 Sp1 polymorphisms on BMD in the Irish population. Calcif Tissue Int 2002; 71: 26-35.
 
7.
Choi JY, Shin A, Park SK, et al. Genetic polymorphisms of OPG, RANK, and ESR1 and bone mineral density in Korean postmenopausal women. Calcif Tissue Int 2005; 77: 152-159.
 
8.
Hsu YH, Niu T, Terwedow HA, et al. Variation in genes involved in the RANKL/RANK/OPG bone remodeling pathway are associated with bone mineral density at different skeletal sites in men. Hum Genet 2006; 118: 568-577.
 
9.
Zajíčková K, Zemanová A, Hill M. Žofková I. Is A163G Polymorphism in the Osteoprotegerin Gene Associated with Heel Velocity of Sound in Postmenopausal Women? Physiol Res 2008; 57 (Suppl. 1): S153-S157.
 
10.
Vidal C, Brincat M, Anastasi X. TNFRSF11B gene variants and bone mineral density in postmenopausal women in Malta. Maturitas 2006; 53: 386-395.
 
11.
Kim JG, Kim JH, Kim JY, et al. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappa B (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women. Menopause 2007; 14: 913-918.
 
12.
Ueland T, Bollerslev J, Wilson SG, et al. No associations between OPG gene polymorphisms or serum levels and measures of osteoporosis in elderly Australian women. Bone 2007; 40: 175-181.
 
13.
Zupan J, Komadina R, Marc J. The relationship between osteoclastogenic and anti-osteoclastogenic pro-inflammatory cytokines differs in human osteoporotic and osteoarthritic bone tissues. J Biomed Sci 2012; 1: 19-28.
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top